Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$0.32
+0.00 (+0.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-3.4M · quality 39.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$64M
P/E
N/A
•EV/EBITDA
-8.5x
↓ROE
-3.4%
↓Gross Margin
16.4%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-24.0%
FCF CAGR
—
FCF margin
-13.5%
FCF / Net income
2.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $25.1M · net income $-1.4M · FCF $-3.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $25.1M | $25.1M | $46.5M | $64.9M | $57.1M |
| Net Income | $-1.4M | $-1.4M | $-7.8M | $1.1M | $3.2M |
| EBITDA | $879873.00 | $879873.00 | $-1.3M | $3.7M | $4.2M |
| EPS | -0.20 | -0.20 | -1.08 | 0.15 | 0.45 |
| Gross Margin | 16.4% | 16.4% | 3.8% | 9.6% | 9.9% |
| Operating Margin | -1.4% | -1.4% | -5.2% | 3.9% | 5.2% |
| Net Margin | -5.7% | -5.7% | -16.7% | 1.7% | 5.5% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.01 | 0.03 | 0.15 |
| Cash Flow | |||||
| Free Cash Flow | $-3.4M | $-3.4M | $-3.4M | $9.4M | $-3.1M |
| Returns | |||||
| ROE | -3.4% | -3.4% | -18.2% | 2.0% | 5.7% |
| Valuation | |||||
| P/E | — | — | — | 39.67 | 44.11 |
| EV/EBITDA | -8.54 | -8.54 | — | 8.14 | 32.00 |
| P/B | 0.05 | 0.05 | 0.65 | 0.81 | 2.47 |
| Growth & Yield | |||||
| Revenue Growth | -46.0% | -46.0% | -28.3% | 13.6% | — |
| EPS Growth | 81.5% | 81.5% | -820.0% | -66.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-97.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.08 → -0.20
Residual
-97.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.